FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin
The FDA concluded that the type 2 diabetes medicine canagliflozin causes an increased risk of leg and foot amputations.
Media formats available
Completing the pre-test is required to access this content.
Pre-Survey
Completing the pre-survey is required to access this content.
